Login
Nuvation Bio Inc. logo

Nuvation Bio Inc.

nuvationbio.com

What Do They Do?

Develops and sells cancer medicines, including a treatment for adults with a specific type of lung cancer, and advances other cancer drug candidates.

How Do They Make Money?

Licensing and collaboration agreements are the larger revenue stream: partners pay upfront and milestone fees, royalties tied to sales and for research services; U.S. customers buy shipped IBTROZI.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Product Revenue
Sold outright

39%
License
Licensed

61%

Who Are Their Customers?

U.S. customers buy IBTROZI from Nuvation Bio; partners Innovent and Nippon Kayaku commercialize taletrectinib in China and Japan.

Do Revenues Turn Into Profits?

No. It lost $204.6M in FY2025.

Operating income, FY2025
−339% of revenue
▲ +64% (Loss) vs FY2024 (−$592.6M, −7527%)
Net income, FY2025
−325% of revenue
▲ +64% (Loss) vs FY2024 (−$567.9M, −7214%)
Free cash flow, FY2025
−289% of revenue
▼ −39% (Loss) vs FY2024 (−$130.6M, −1659%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +243%
vs $13.1M in Q3 FY2025
Net income
▲ +25% (Loss)
vs −$55.8M in Q3 FY2025
License share of revenue vs 41.1% in Q3 FY2025

From development to sales The earlier report described Nuvation as clinical-stage and focused on candidates; the latest describes a U.S. launch of IBTROZI and commercial operations.

Pipeline focus The earlier report highlighted an oncology candidate and a drug-conjugate program; the latest centers its clinical pipeline on taletrectinib and safusidenib, while continuing preclinical drug-conjugate work.

Territorial partnerships The earlier report said it held worldwide development and commercial rights and planned to consider collaborations; the latest describes partners commercializing taletrectinib in China and Japan and a partnership with Eisai for Europe.

Revenue over time
Product Revenue License Product
$100M$50M$0

Who Do They Compete With?

Competes with AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, Roche, Nuvalent, Servier, and Rigel

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support